预约演示

更新于：2025-05-07

Oxaliplatin

奥沙利铂

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名

Dendrimer-Oxaliplatin (Starpharma)、Diaminocyclohexane Oxalatoplatinum、GSOX

+ [34]

靶点

DNA

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [5]

在研适应症

小肠癌胃癌胰腺癌+ [18]

非在研适应症

急性髓性白血病晚期胆管癌晚期乳腺癌+ [91]

原研机构

Sanofi

在研机构

Merck Sharp & Dohme Corp.

南京制药厂有限公司

Yakult Honsha Co., Ltd.

+ [6]

非在研机构

Genentech, Inc.

Eli Lilly & Co.

Aventis Pharmaceuticals, Inc.

+ [19]

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2000-01-01),

肿瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、加速批准 (美国)

登录后查看时间轴

结构/序列

分子式C8H14N2O4Pt

InChIKeyZROHGHOFXNOHSO-BNTLRKBRSA-L

CAS号61825-94-3

关联

2,440

项与奥沙利铂相关的临床试验

NCT05296005

/ Withdrawn临床1期IIT

Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

开始日期2025-12-31

申办/合作机构

Ohio State University Comprehensive Cancer Center

NCT06780111

/ Not yet recruiting临床1/2期

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts.
Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing.
Researchers want to learn about giving pembrolizumab and ifinatamab deruxtecan (I-DXd), a study medicine, with or without chemotherapy to treat ESCC. I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.
The main goal of this study is to learn about the safety of I-DXd and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.

开始日期2025-08-07

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

NCT06905509

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)

This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP/X and Gem/Ox, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.

开始日期2025-08-01

申办/合作机构

University of California, Davis

[+1]

100 项与奥沙利铂相关的临床结果

登录后查看更多信息

100 项与奥沙利铂相关的转化医学

登录后查看更多信息

100 项与奥沙利铂相关的专利（医药）

登录后查看更多信息

21,946

项与奥沙利铂相关的文献（医药）

2025-12-31·RENAL FAILURE

Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis

Article

作者: Wang, Wei ; Wang, Yiwei ; Fan, Shuling

OBJECTIVES:

Onconephrology is an expanding subspecialty focused on the management of cancer patients with renal injury. This study used a comprehensive bibliometric analysis to emphasize the need for cooperation between oncologists and nephrologists, exploring current trends and future research areas in onconephrology.

METHODS:

Relevant literature on onconephrology published between 1 January 2000 and 27 April 2024 was retrieved from the Science Citation Index Expanded of the Web of Science Core Collection, followed by manual screening. Bibliometric analyses were performed using CiteSpace, VOSviewer, and Bibliometrix software.

RESULTS:

A total of 1,853 publications, including 1,647 articles and 206 reviews, by 11,606 authors from 2,757 institutions in 73 countries, were analyzed. Annual publications generally follow a steadily increasing trend, ranging from 25 to 161 documents. The United States (n = 464), The University of Texas MD Anderson Cancer Center (n = 39), Meletios A. Dimopoulos (n = 21), and Nephrology Dialysis Transplantation (n = 35) were the most productive country, institution, author, and journal, respectively. Immune checkpoint inhibitors, glomerular filtration rate, and cisplatin were clusters of highly cited references after 2015. Oxaliplatin, calcium, open-label, and thrombotic microangiopathy were trending topics after 2020. Outcome, acute kidney injury, immunotherapy, and chronic kidney disease were keyword bursts that persisted through 2024.

CONCLUSION:

Current research of onconephrology is focusing on chemotherapeutic nephrotoxicity, kidney function assessment, dosing of chemotherapeutic agents in chronic kidney disease, glomerular disease in cancer, immunotherapy, and electrolyte disturbances. Future directions in this field include clinical trials and thrombotic microangiopathy.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Comparative effects of arsenic trioxide and chemotherapy on Chk1 and CDC25 gene expression in gastric cancer cells AGS and MKN45: a potential therapeutic strategy

Article

作者: Majd, Ahmad ; Nikbakht, Mohsen ; Mousavi, Seyed Asadoullah ; Babaei, Shadi

BACKGROUND:

Gastric cancer (GC) remains a significant global health burden, particularly in East Asia, where it is a leading cause of cancer-related morbidity and mortality. Despite advancements in chemotherapy, the development of chemoresistance continues to undermine the efficacy of standard treatments such as Docetaxel and Oxaliplatin. Arsenic trioxide (ATO) has emerged as a potential therapeutic agent capable of overcoming resistance by targeting DNA repair mechanisms, particularly through the downregulation of Checkpoint Kinase 1 (Chk1). This study investigates the cytotoxic effects of ATO and its capacity to enhance chemotherapy efficacy in GC cells.

METHODS:

AGS and MKN-45 gastric cancer cell lines were exposed to ATO, Docetaxel, Oxaliplatin, and their combinations. Cell viability was assessed via the MTT assay, while Chk1 and CDC25 expressions at the mRNA and protein levels was analyzed using real-time PCR and Western blotting. Statistical analyses were performed using ANOVA and Tukey's post hoc test.

RESULTS:

The MTT assay revealed significant dose- and time-dependent reductions in cell viability, with combination treatments achieving the most pronounced effects. The greatest cytotoxicity was observed with 4 µM ATO combined with 2500 µM Docetaxel or 100 µM Oxaliplatin, showing a high level of statistical significance (p < 0.0001). Additionally, ATO monotherapy significantly downregulated Chk1 and CDC25 expressions (p < 0.05), while its combination with chemotherapeutic agents further enhanced Chk1 and CDC25 suppressions, with ATO-Docetaxel demonstrating the most pronounced effect (p < 0.01).

CONCLUSIONS:

These findings highlight ATO's potential to sensitize GC cells to chemotherapy by impairing DNA repair mechanisms and inducing synergistic cytotoxicity. ATO holds promise as an adjuvant therapeutic agent for overcoming chemoresistance in gastric cancer.

2025-12-01·Journal of Gastrointestinal Cancer

The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy

Article

作者: Gultom, Fajar Lamhot ; Basir, Ibrahim ; Fauza, Dilafitria ; Kurniawan, Dicky ; Steven, Ricci ; Budiyati, Akterono Dwi ; Gunarsa, Ralph Girson ; Sudoyo, Aru Wisaksono

Abstract:

Purpose:

Increased level of circulating myeloid -derived suppressor cells (MDSCs) in colorectal cancer (CRC) patients has been associated with higher tumor stage and poorer survival due to poorer response to therapeutic agents. However, studies reported inconsistent results on how chemotherapeutic agents affecting the depletion of two major types of MDSCs, polymophonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). The present study aims to learn deeper on the dynamic changes of circulating MDSCs, especially in response to oxaliplatin-based treatment in CRC patients.

Methods:

This was a prospective study that recruited 30 treatment-naive patients with varying stages of CRC who were scheduled to receive oxaliplatin-based chemotherapy. Blood sampling was conducted prior to and at several time points during and after chemotherapy. Multicolor flow cytometry assay was used to analyse the proportion of HLA-DR– and CD33+ with CD15+ (PMN-MDSCs) or CD14+ (M-MDSCs) cells within peripheral blood mononuclear cells (PBMCs). Other essential tumor biomarkers such as carcinoembryonic antigen (CEA) and tumor-infiltrating lymphocytes (TILs) were also assessed. As a control, 14 healthy subjects were recruited in this study.

Results:

Indonesian treatment-naive CRC patients exhibited significantly higher circulating PMN-MDSCs compared to healthy subjects (p = 0.003), while M-MDSCs levels showed no significant difference between the groups (p = 0.890). Following chemotherapy, the MDSCs level demonstrated dynamic changes. Interestingly, a subgroup of CRC patients with decreased in both PMN- and M-MDSCs levels on D-14 of chemotherapy consistently showed a significant reduction in MDSCs levels during and after therapy completion compared to baseline (p = 0.0078).

Conclusions:

Circulating MDSCs level, particularly PMN-MDSCs, in CRC patients, was significantly higher compared to healthy subjects. Changes in both circulating PMN- and M-MDSCs levels at D-14 chemotherapy might have prognostic value in oxaliplatin-based chemotherapy.

1,356

项与奥沙利铂相关的新闻（医药）

21 小时之前

·Insight数据库

罗氏 CD3/CD20 双抗新适应症在华获批

5 月 7 日，罗氏宣布，其 CD3/CD20 双抗新药格菲妥单抗（Glofitamab，商品名：高罗华、Columvi）新适应症已获得国家药监局上市批准，联合吉西他滨与奥沙利铂（GemOx）用于治疗不适合自体造血干细胞移植（ASCT）的复发或难治性弥漫大 B 细胞淋巴瘤非特指型（DLBCL NOS）成人患者（2L+ DLBCL）。此前 2023 年 11 月，该产品在中国获批单药用于治疗既往接受过至少两线系统性治疗的复发或难治性弥漫大 B 细胞淋巴瘤（DLBCL）成人患者。来源：罗氏官微此次获批基于 STARGLO 研究。该研究旨在探索格菲妥单抗联合吉西他滨、奥沙利铂（Glofit-GemOx）对比利妥昔单抗联合吉西他滨、奥沙利铂（R-GemOx）在接受过 ≥1 线治疗且不适合移植 R/R DLBCL 患者中的疗效和安全性。该研究结果首次显示了 CD20/CD3 双抗拥有为二线不适合移植的 R/R DLBCL 患者人群带来生存获益的潜力。具体来说，接受格菲妥单抗联合治疗的患者，中位总生存期几乎可以实现翻倍，中位 OS 达 25.5 个月（R-GemOx 组 12.9 个月）；其中位无进展生存期翻近四倍（13.8 个月 VS. 3.6 个月），总缓解率和完全缓解率相比于对照组分别提高 27.7% 和 33.2%。同时，格菲妥单抗联合治疗的安全性良好，有更多患者完成了完整的治疗周期。格菲妥单抗对不适合移植的 R/R DLBCL 患者展现出了显著的生存期和缓解率改善，以及可控的安全性，有效弥补了当前该领域二线治疗的不足。作为一类无需定制化的即用型T细胞疗法，格菲妥单抗依托新型的 2:1 双抗结构，可同时靶向结合 2 种抗原分子——T 细胞表面的 CD3 抗原和 B 细胞表面的 CD20 抗原，激活、扩增、重定向T细胞的同时，可带来更强的 B 细胞抓取能力和作用效力，在安全耐受的前提下加强杀伤肿瘤细胞的能力。封面来源：企业logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：月牙PR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn

上市批准临床结果细胞疗法

23 小时之前

·Pharma CMC

刚刚，罗氏「格菲妥单抗」新适应症获批上市

刚刚，罗氏宣布其创新双特异性抗体格菲妥单抗（商品名：高罗华®）新适应症已获得中国国家药品监督管理局的上市批准，联合吉西他滨与奥沙利铂（GemOx）用于治疗不适合自体造血干细胞移植（ASCT）的复发或难治性弥漫大B细胞淋巴瘤非特指型（DLBCL NOS）成人患者（2L+ DLBCL）。格菲妥单抗注射液为CD20×CD3双特异性抗体，于2023年在中国首次获批，单药用于治疗既往接受过至少两线系统性治疗的复发或难治性弥漫大B细胞淋巴瘤（DLBCL）成人患者。弥漫大B细胞淋巴瘤（DLBCL）侵袭性强，恶性程度高，有高达30-40%的淋巴瘤患者会在接受初始标准治疗后发生疾病进展或在初始缓解后复发。尽管其二线治疗不乏不同的治疗方案，但无论自体造血干细胞移植（ASCT）标准方案或CAR-T疗法创新方案均有所局限。格菲妥单抗本次获批是基于STARGLO研究。该研究旨在探索格菲妥单抗联合吉西他滨、奥沙利铂（Glofit-GemOx）对比利妥昔单抗联合吉西他滨、奥沙利铂（R-GemOx）在接受过≥1线治疗且不适合移植R/R DLBCL患者中的疗效和安全性。该研究结果首次显示了CD20/CD3双特异性抗体拥有为二线不适合移植的R/R DLBCL患者人群带来生存获益的潜力。根据STARGLO研究结果，接受格菲妥单抗联合治疗的患者，中位总生存期几乎可以实现翻倍，中位OS达25.5个月（R-GemOx组12.9个月）；其中位无进展生存期翻近四倍（13.8个月 VS. 3.6个月），总缓解率和完全缓解率相比于对照组分别提高 27.7% 和 33.2%。同时，格菲妥单抗联合治疗的安全性良好，有更多患者完成了完整的治疗周期。格菲妥单抗对不适合移植的R/R DLBCL患者展现出了显著的生存期和缓解率改善，以及可控的安全性，有效弥补了当前该领域二线治疗的不足。

上市批准免疫疗法细胞疗法临床结果

2025-05-07

·罗氏制药

高罗华®新适应症在华获批，丰富复发/难治弥漫大B细胞淋巴瘤二线治疗选择

【中国上海，2025年5月7日】罗氏制药中国宣布，创新双特异性抗体高罗华®（英文商品名：Columvi®，中英文通用名：格菲妥单抗/Glofitamab）新适应症已获得中国国家药品监督管理局的上市批准，联合吉西他滨与奥沙利铂（GemOx）用于治疗不适合自体造血干细胞移植（ASCT）的复发或难治性弥漫大B细胞淋巴瘤非特指型（DLBCL NOS）成人患者（2L+ DLBCL）。作为全球首个[1]对复发/难治弥漫大B细胞淋巴瘤（R/R DLBCL）患者进行固定周期治疗的双特异性抗体，高罗华®于2023年在中国获批单药用于治疗既往接受过至少两线系统性治疗的复发或难治性弥漫大B细胞淋巴瘤（DLBCL）成人患者，开启了我国淋巴瘤治疗的“双抗时代”。伴随此次适应症拓展，高罗华®再树里程碑，将为更早期的患者带去获益，有望革新DLBCL二线治疗格局。至此，凭借创新抗体药物偶联物（ADC）优罗华®和高罗华®，罗氏实现了DLBCL初治到二线治疗的创新“一条龙”落地，将全程助力患者争取更多长期生存机会。弥漫大B细胞淋巴瘤（DLBCL）侵袭性强，恶性程度高，有高达30-40%的淋巴瘤患者会在接受初始标准治疗后发生疾病进展或在初始缓解后复发[2]。尽管其二线治疗不乏不同的治疗方案，但无论自体造血干细胞移植（ASCT）标准方案或CAR-T疗法创新方案均有所局限。尤其对于因为治疗强度、年龄或合并其他疾病等因素而不适合ASCT的50%以上R/R DLBCL患者[3]而言，在CSCO淋巴瘤诊疗指南推荐中，临床试验仍然是二线治疗的重要选择，可见仍需更高效和更可及的治疗方案。“DLBCL越复发越难治，如果二线治疗无法达到缓解，后续治疗选择将越来越少。因此，找到有效且安全的二线疗法改善患者预后，在更早阶段抓住控制疾病的契机，是提高DLBCL生存率的关键一环。近年来，T细胞免疫疗法飞速发展，正在引领着DLBCL二线和后线治疗的全面革新。其中，CAR-T由于制备期长，管理程序冗长复杂，加之可及性等问题，其在临床中的应用范围仍有较大限制。如今，作为‘即用型’T细胞疗法的双抗药物，临床适应症应用范围拓宽，为DLBCL二线治疗带来了全新解题思路，有望为更多患者带来获益。”此次获批基于STARGLO研究[4]。该研究旨在探索格菲妥单抗联合吉西他滨、奥沙利铂（Glofit-GemOx）对比利妥昔单抗联合吉西他滨、奥沙利铂（R-GemOx）在接受过≥1线治疗且不适合移植R/R DLBCL患者中的疗效和安全性。该研究结果首次显示了CD20/CD3双特异性抗体拥有为二线不适合移植的R/R DLBCL患者人群带来生存获益的潜力[5]。“根据STARGLO研究结果，接受高罗华®联合治疗的患者，中位总生存期几乎可以实现翻倍，中位OS达25.5个月（R-GemOx组12.9个月）；其中位无进展生存期翻近四倍（13.8个月 VS. 3.6个月），总缓解率和完全缓解率相比于对照组分别提高 27.7% 和 33.2%。同时，高罗华®联合治疗的安全性良好，有更多患者完成了完整的治疗周期。高罗华®对不适合移植的R/R DLBCL患者展现出了显著的生存期和缓解率改善，以及可控的安全性，有效弥补了当前该领域二线治疗的不足。作为一类无需定制化的即用型T细胞疗法，高罗华®依托新型的2:1双抗结构，可同时靶向结合2种抗原分子——T细胞表面的CD3抗原和B细胞表面的CD20抗原，激活、扩增、重定向T细胞的同时，可带来更强的B细胞抓取能力和作用效力，在安全耐受的前提下加强杀伤肿瘤细胞的能力。因此，这一疗法可以帮助患者获得早期、深度的缓解，减小疾病进展风险，也有利于降低后续治疗费用。长远来看，高罗华®采用12周期的固定疗程，可以减少患者就诊的次数、往返医院和住所所需的成本和时间等，有望帮助节省后线治疗医疗资源。”面对治疗阶段的递增以及部分创新治疗可及的局限性，经济负担是DLBCL患者不得不面对的一个问题，如今国家多层次医疗保障体系的逐步完善有望缓解这一局面。根据《2022中国弥漫性大B细胞淋巴瘤患者生存状况白皮书》调研结果，DLBCL患者的医疗自费支出占家庭收入均值的157%，远超于国际公认的灾难性家庭支出标准（40%），其中弥漫大B细胞淋巴瘤患者平均年医疗支出在31.8万元，复发患者的医疗支出平均则在43.6万元。在基本医保和商业保险、惠民保类的城市定制型商业补充医疗保险等多层次医疗保障体系的支持下，DLBCL患者应对支付难题有了更多的创新解决方案。“创新药被纳入医保前，多层次保障可以起到很好的桥接作用。以高罗华®为例，这一创新疗法已被纳入多个城市的惠民保项目，可行性和可支付性正逐步提升。更令人期待的是，它也有望于近期被纳入‘复发难治险’商业险，这意味着从癌症复发初始，到可能出现转移的阶段，均可以在保障范围内，实现全病程守护。在DLBCL领域，用于二线治疗的T细胞疗法尚未被医保覆盖，可支付性问题成为摆在复发/难治患者面前的一座大山，患者治疗需求仍存在未被满足的部分。我们也期待更多像高罗华®这样创新程度高、临床价值巨大和患者获益显著的DLBCL药物的可以进入基本医保，让更多患者真正能够用上创新药物，获得拥抱新生的机会。”“高罗华®持续为R/R DLBCL治疗发展注入新的动力，此次新适应症拓展也再次彰显了其创新潜力。罗氏血液研发始终立足于患者未尽之需，从美罗华®、优罗华®到高罗华®，我们用‘以超越致敬经典’的方式建立起全面覆盖DLBCL一线、二线到后线治疗的创新治疗模式，并将这些创新方案快速带到中国，致力于让每一个治疗阶段的DLBCL患者都能尽早实现创新治疗可及。”“国家医疗体制改革持续深入，推进药物可及、真正惠及患者已成为重要目标，我们将全力助力实现创新方案的可行性、可及性与可负担性。在国家药监部门持续优化审评审批机制的政策东风下，我们迎来‘进博宝宝’高罗华®新适应症的获批，见证这一创新治疗方案惠及更广泛的弥漫大B细胞淋巴瘤患者。作为‘先患者之需而行’的践行者，未来我们将继续为提升药物可及性和可支付性努力，通过积极参与医保谈判，同时探索和商业保险及惠民保项目等更多创新支付渠道的联合，让前沿治疗方案及时触达每位需要的患者，最终助力‘健康中国2030’宏伟蓝图的实现。”参考文献：[1]FDA approves Roche’s Columvi, the first and only bispecific：https://www.globenewswire.com/news-release/2023/06/16/2689505/0/en/FDA-approves-Roche-s-Columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html[2]Coiffier B, et al. Blood. 2010;116(12):2040-2045.[3]Hoffmann MS, et al. Transplant Cell Ther. 2023;29(7):440-448.[4]Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-1954. doi:10.1016/S0140-6736(24)01774-4[5]Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma：https://www.roche.com/media/releases/med-cor-2024-06-15#:~:text=Basel%2C%2015%20June%202024%20-%20Roche%20%28SIX%3A%20RO%2C,2024%20Congress%20as%20a%20late-breaking%20oral%20presentation.%2011.本新闻公告旨在发布研发注册进展信息，仅供中国境内医疗卫生专业人士参阅，非广告用途。2.罗氏不对任何药品和/或适应症作推荐。3.本新闻公告中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。更多新闻一年注射两次！罗氏制药罗可适®在华获批用于治疗复发型和原发进展型多发性硬化症38年研发突破！罗氏获批中国首个针对PIK3CA突变的靶向创新药，为乳腺癌患者带来新希望

免疫疗法细胞疗法CSCO会议抗体药物偶联物临床结果

100 项与奥沙利铂相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01790	奥沙利铂	L01XA03	DB00526

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
小肠癌	日本	Takata Pharmaceutical Co. Ltd.	2018-09-21
小肠癌	日本	Yakult Honsha Co., Ltd.	2018-09-21
胃癌	日本	Takata Pharmaceutical Co. Ltd.	2015-03-20
胃癌	日本	Yakult Honsha Co., Ltd.	2015-03-20
胰腺癌	日本	Yakult Honsha Co., Ltd.	2013-12-20
胰腺癌	日本	Takata Pharmaceutical Co. Ltd.	2013-12-20
结直肠癌	美国	Sanofi-Aventis U.S. LLC	2007-01-10
晚期结直肠腺癌	澳大利亚	Medis Pharma Pty Ltd.	2006-11-28
结肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
直肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
肿瘤	中国	南京制药厂有限公司	2000-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
RAS 野生型结直肠癌	临床3期	法国	Hoffmann-La Roche, Inc.	2013-10-30
RAS 野生型结直肠癌	临床3期	爱尔兰	Hoffmann-La Roche, Inc.	2013-10-30
RAS 野生型结直肠癌	临床3期	以色列	Hoffmann-La Roche, Inc.	2013-10-30
晚期胃癌	临床3期	韩国	Sanofi SA	2011-12-30
结肠癌肝转移	临床3期	中国	Sanofi	2008-01-01
晚期肝细胞癌	临床3期	中国	Sanofi	2007-03-01
晚期肝细胞癌	临床3期	韩国	Sanofi	2007-03-01
晚期肝细胞癌	临床3期	中国台湾	Sanofi	2007-03-01
晚期肝细胞癌	临床3期	泰国	Sanofi	2007-03-01
结肠转移性腺癌	临床3期	美国	Eli Lilly & Co.	2003-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	结直肠癌	-	Obatoclax	構製範範鑰膚網鏇醖窪(簾積膚顧鏇齋鏇觸願醖) = 醖繭築壓鏇餘簾醖膚齋壓選築廠憲窪網鑰鹽蓋 (顧糧構簾餘顧選衊積鏇 )	积极	2025-04-27
NCT03861702 (BTCRC-GI15-067, CTgov)	临床2期	局部晚期胰腺腺癌	28	LEUCOVORIN CALCIUM+Liposomal Irinotecan+Oxaliplatin+Fluorouracil	範夢獵齋鬱積獵齋窪蓋 = 遞淵醖鹹鹹簾淵艱構衊憲顧鬱繭壓顧齋艱蓋艱 (鹽壓壓鬱糧憲窪網淵醖, 顧鏇醖鹹鹽遞衊衊襯鬱 ~ 範繭鹹遞襯夢壓積廠繭) 更多	-	2025-04-18
NCT04380337 (SHORT-FOX, CTgov)	临床2期	直肠癌 \| 直肠腺癌	38	IMRT+LEUCOVORIN CALCIUM+irinotecan+oxaliplatin+capecitabine+Fluorouracil	築壓築膚鹹網選鹽蓋蓋 = 願鏇憲鹹鬱壓齋網壓鑰網築膚蓋鹽選積鹽夢積 (鑰構艱簾齋壓網齋壓衊, 夢鹹齋築膚憲餘網壓衊 ~ 襯顧鹽襯壓窪襯膚鏇選) 更多	-	2025-02-25
JPRN-UMIN000022210 (Phase I/II clinical trial of preoperative docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for esophagogastric junction adenocarcinoma, ASCO_GI2025)	临床1/2期	胃食管交界处腺癌新辅助 \| 辅助	40	Docetaxel 60 mg/m²	窪簾齋襯鹽築壓範獵淵(積築觸廠繭廠壓艱淵鑰) = 鑰艱觸襯獵蓋簾簾糧願網鏇繭鹽艱構齋構衊窪 (窪選壓遞蓋網淵選艱衊 ) 更多	积极	2025-01-23
				S-1 120 mg/body	齋築顧鑰鹽網醖糧窪壓(衊廠廠積範鹹襯膚鏇選) = 鹹選繭遞鏇醖艱餘選範範廠齋蓋鬱蓋醖網窪鹹 (顧簾襯網夢膚衊顧鬱築 ) 更多
JPRN-UMIN000013036 (ACHIEVE-2, ASCO_GI2025)	临床3期	结肠癌辅助	525	3-month mFOLFOX6/CAPOX treatment	遞憲獵餘蓋鬱網築鑰襯(襯構範醖糧範選蓋窪願) = The incidence of long-lasting PSN was significantly lower at 3 months than at 6 months of therapy 窪積鹽壓製鹽網鑰鑰簾 (憲餘繭築積鏇壓獵膚齋 ) 更多	积极	2025-01-23
				6-month mFOLFOX6/CAPOX treatment
NCT05627635 (ASCO_GI2025)	临床1期	微卫星稳定型结直肠癌 MSS	14	Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)	繭簾蓋鏇餘鏇窪襯鹽選(衊淵顧鬱壓觸築蓋窪鏇) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism 膚築醖鑰製鹽獵醖簾構 (構選顧網築顧鹽構製齋 ) 更多	积极	2025-01-23
ASCO_GI2025	N/A	晚期肝细胞癌一线	-	Lenvatinib plus FOLFOX-HAIC	觸壓積獵衊範齋壓簾遞(鏇構積繭鹹廠鑰鹽築選) = Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group 壓遞獵範獵簾範網廠願 (壓鹽製選鹹獵簾齋顧餘 ) 更多	积极	2025-01-23
				Lenvatinib alone
JPRN-jRCTs031200094 (ASCO_GI2025)	临床2期	食管鳞状细胞癌新辅助	54	Neoadjuvant FLOT therapy	獵鏇窪願構醖鏇繭鏇憲(艱鹹廠壓網餘鏇積衊觸) = 構艱夢衊糧壓廠獵構淵衊齋糧鹽製構簾廠醖鬱 (鏇觸網觸憲鑰簾壓鑰蓋, 29.8 ~ 57.7) 更多	积极	2025-01-23
NCT03500874 (HARVEST trial, Pubmed \| Eur J Cancer)	临床3期	结直肠癌肝转移辅助 RAS/BRAF mutations \| positive postoperative ctDNA methylation	92	Standard systemic chemotherapy only	鑰齋膚襯憲膚鹽鹹遞鬱(餘淵遞憲鏇鏇遞鹽製願) = 遞衊窪齋願觸膚構選憲憲餘構襯醖範築壓醖願 (鹹選鬱蓋築壓積獵壓選 )	积极	2025-01-01
				Standard systemic chemotherapy + HAI-FUDR	鑰齋膚襯憲膚鹽鹹遞鬱(餘淵遞憲鏇鏇遞鹽製願) = 選襯淵鏇獵蓋壓廠鏇夢憲餘構襯醖範築壓醖願 (鹹選鬱蓋築壓積獵壓選 )